Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BRAF mutation predicts MEK-dependence in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Pratilas, C. A.; Halilovic, E.; Sawai, A.; Grbovic-Huezo, O.; Rosen, N.; Solit, D. B.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Impact of risk-reducing oophorectomy on quality of life in women at risk for ovarian cancer
    Meeting Abstract

    McArthur, H. L.; Hensley, M.; Brown, C. L.; Chi, D. S.; Offit, K.; Hurley, K.; Li, Y.; Gemignani, M. L.; Robson, M. E.; Barakat, R. R.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase I trial of alvespimycin (KOS-1022; 17-DMAG) and trastuzumab (T)
    Meeting Abstract

    Miller, K.; Rosen, L. S.; Modi, S.; Schneider, B.; Roy, J.; Chap, L.; Paulsen, M.; Kersey, K.; Hannah, A.; Hudis, C.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC)
    Meeting Abstract

    Kaufman, P. A.; Broadwater, G.; Lezon-Geyda, K.; Dressler, L. G.; Berry, D.; Friedman, P.; Winer, E. P.; Hudis, C.; Ellis, M. J.; Seidman, A. D.; more...
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): Cardiac safety
    Meeting Abstract

    Dickler, M. N.; Traina, T.; Panageas, K.; Steingart, R.; Dang, C.; Fornier, M.; Sugarman, S.; Norton, L.; Hudis, C.; Rugo, H.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report
    Meeting Abstract

    Conlin, A. K.; Seidman, A. D.; Moynahan, M. E.; Traina, T.; Mace, J. R.; Meiri, E.; Bach, A.; Edwards, C.; Hudis, C. A.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer
    Meeting Abstract

    Chandarlapaty, S.; Scaltriti, M.; Baselga, J.; Ye, Q.; Solit, D.; Norton, L.; Rosen, N.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)
    Meeting Abstract

    Beeram, M.; Krop, I.; Modi, S.; Tolcher, A.; Rabbee, N.; Girish, S.; Tibbitts, J.; Holden, S.; Lutzker, S.; Burris, H.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • The PI3K/AKT and MAPK signaling cooperate to mediate translational initiation and cell survival in human tumors
    Meeting Abstract

    She, Q. B.; Ye, Q.; Zhen, W.; Solit, D.; Rosen, N.
    Cancer Research (2007)

    Fulltext@MSK | Save
  • Activating mutation in B-RAF disables normal feedback inhibition of MEK and results in increased output of the RAF/MEK/MAPK signaling pathway
    Meeting Abstract

    Pratilas, C. A.; Taylor, B.; Nelander, S.; Grbovic-Huezo, O.; Viale, A.; Solit, D.; Sander, C.; Rosen, N.
    Cancer Research (2007)

    Fulltext@MSK | Save